Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy

NCT00686920 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.

NCT NCT00686920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00686920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy
Lead sponsor
Bausch Health Americas, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 7, 2007
Completion date
December 8, 2010
Enrollment
322 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic encephalopathy